Developer docs
API playgroundTry for free, no card

Search company profiles

Lifera

Full company profile

uuid000g1wx

Namestring
Lifera
Legal namestring
Lifera
Websiteurl
lifera.com.sa
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Lifera is a biopharmaceutical company established in June 2023 by Saudi Arabia's Public Investment Fund (PIF) to develop the Kingdom's domestic biopharmaceutical manufacturing capacity and enable the National Biotechnology Strategy under Vision 2030. The company is wholly owned by PIF (Saudi Arabia's sovereign wealth fund) and operates from Riyadh. It serves global pharmaceutical clients seeking to localize drug manufacturing in Saudi Arabia and the MENA region, as well as healthcare providers requiring genomic testing and precision medicine services. Lifera runs two core business units: Biomanufacturing, via subsidiary SaudiBio, focused on sterile and aseptic drug product and drug substance manufacturing; and Lifera Omics (MultiOmics), providing high-throughput genetic testing, bioinformatics, and research services.

The Biomanufacturing platform centers on the SaudiBio facility in Sudair Industrial City, 110 km north of Riyadh, built on a 30,000 sqm plot with expansion potential. Plant 1 features isolator-based, fully automated formulation and filling under cGMP, with capacity to produce up to 120 million annual units across vials (liquid and lyophilized) in 2R–50R formats, pre-filled syringes, and cartridges. Equipment is sourced from premium global suppliers including Syntegon, Groninger, SKAN, and Pierre Guerin, with commissioning targeted for 2027 under EMA Annex 1 and SFDA standards. The Lifera Omics business operates a proprietary biodatabank with over 800,000 patients (60,000+ Saudi Arabian) and over 70 million unique variants, supporting genomics, multiomic testing, and AI-enabled drug discovery focused on disease areas endemic to MENA populations.

Lifera's revenue model combines (1) CDMO services — manufacturing fees, technology transfer agreements, and long-term supply contracts — with global pharmaceutical partners (anchored by a seven-year insulin localization arrangement with Novo Nordisk, a Jamjoom Pharma 51/49 joint venture for vaccines/biologics/biosimilars, and exploratory MoUs with Pfizer, Sanofi, and MSD), and (2) genomic and multiomic testing, bioinformatics, and research services delivered to healthcare providers, hospitals, and biopharma clients. Pricing is enterprise quote-based and not publicly disclosed. Go-to-market is direct B2B engagement, supplemented by event-driven partnership announcements such as those made at the Global Health Exhibition 2025.

Short descriptiontext

Lifera is a PIF-owned Saudi biopharmaceutical company operating SaudiBio for aseptic drug product CDMO manufacturing and Lifera Omics for genomic testing and bioinformatics, serving global pharmaceutical clients and regional healthcare providers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRiyadh, Saudi Arabia
HQ citystring
Riyadh
HQ countrystring
Saudi Arabia
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical manufacturing, contract development manufacturing, multiomics testing services, genomic bioinformatics platform, sterile drug product filling
Industry3 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Contract Manufacturing (CDMO)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Biomanufacturing CDMO Services
TypeManaged Services
Description

Contract development and manufacturing organization providing commercial-scale drug product and drug substance manufacturing services to pharmaceutical companies. Revenue generated through manufacturing fees, technology transfer agreements, and long-term supply contracts with global pharma clients. SaudiBio facility performs formulation, fill, labeling and packaging of biotherapeutics, vaccines, and other biologics.

openpr.com
2Omics and Genetic Testing Services
TypeProfessional Services
Description

Genomic and multiomic testing services provided to clinical, population health programs, and pharmaceutical clients. Revenue derived from diagnostic testing, bioinformatics services, and research partnerships with healthcare systems and biopharma companies.

lifera.com.sa
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Infrastructure, Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1SaudiBio
Description

State-of-the-art biopharmaceutical manufacturing facility located in Sudair Industrial City, 110 km north of Riyadh. Specializes in commercial drug product manufacturing including formulation, fill, labeling, and packaging of vials, prefilled syringes, and cartridges in both liquid and lyophilized formats.

lifera.com.sa
+1 more record
Core offering1 text field

Lifera provides commercial-scale contract development and manufacturing (CDMO) services for biopharmaceuticals through its subsidiary SaudiBio, covering drug substance and drug product manufacturing including formulation, aseptic filling, labeling, and packaging of biotherapeutics, vaccines, monoclonal antibodies, plasma therapeutics, cell and gene therapies, and innovative small molecules. The company also offers high-throughput genomic and multiomic testing, bioinformatics, and precision medicine services through Lifera Omics, supported by a proprietary biodatabank enriched for Saudi Arabian population genomics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Expected to create over 200 high-skilled jobs in Saudi Arabia by 2027/28 through Novo Nordisk insulin localization
+2 more records
Product overview1 text field

Lifera is a biopharmaceutical company owned by Saudi Arabia's Public Investment Fund operating two primary business units: Biomanufacturing (including subsidiary SaudiBio) and Lifera Omics (MultiOmics). The Biomanufacturing division provides commercial-scale sterile drug product manufacturing services including formulation, fill, labeling, and packaging of biotherapeutics, vaccines, and other biologics, with SaudiBio Plant 1 targeting 120 million annual units capacity. The Lifera Omics platform delivers high-throughput genetic testing, bioinformatics, and precision medicine services powered by a proprietary biodatabank enriched for Saudi population genomic data. These offerings work together to enable end-to-end capabilities from genetic testing and drug discovery through commercial manufacturing of biologics, supporting Saudi Arabia's National Biotechnology Strategy and Vision 2030 goals.

Product and service2 records
1Biomanufacturing Services (CDMO)
CategoryContract Development and Manufacturing (CDMO)
Description

State-of-the-art sterile and aseptic biopharmaceutical drug product and drug substance manufacturing services including formulation, fill, labeling, and packaging of biotherapeutics, vaccines, monoclonal antibodies, plasma therapeutics, cell and gene therapies, and innovative small molecules. Provided through the SaudiBio facility with isolator-based, fully automated cGMP-aligned filling lines and up to 120 million annual units capacity across liquid and lyophilized formats for vials, prefilled syringes, and cartridges. Targeted at global pharmaceutical companies seeking manufacturing localization.

2Lifera Omics (MultiOmics Testing and Bioinformatics Services)
CategoryGenomic and Multiomic Testing Services
Description

High-throughput genomic and multiomic testing, bioinformatics, and precision medicine services for clinical diagnostics, population health programs, and pharmaceutical research clients. Powered by a proprietary biodatabank with over 800,000 patients including 60,000+ Saudi Arabian individuals and 70+ million unique variants. Provided to healthcare providers, hospitals, research centers, and biopharma R&D teams in compliance with HIPAA, GDPR, and Saudi PDPL.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Jamjoom Pharma
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-27
Description

Joint venture announced at Global Health Exhibition for development, manufacture, and commercialization of vaccines, biologics, and biosimilars in Saudi Arabia. Lifera holds 51% majority stake, Jamjoom Pharma holds 49% through subscription to 4,900 shares at SAR 100 per share. JV to build, own, and operate a manufacturing facility in Saudi Arabia. Transaction received no-objection certificate from General Authority for Competition.

lifera.com.sa
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-27
Description

MoU signed at Global Health Exhibition 2025 to explore local pharmaceutical manufacturing opportunities in Saudi Arabia. Partnership supports Saudi Vision 2030 goals for biopharmaceutical industry development, technology transfer, and reducing reliance on pharmaceutical imports. Aims to position Saudi Arabia as a regional life sciences hub while strengthening Saudi-U.S. investment ties.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-27
Description

MoU signed with Lifera to explore vaccine production opportunities in Saudi Arabia. Partnership announced at Global Health Exhibition 2025 as part of broader life sciences investments exceeding $625 million at the event.

4MSD
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-27
Description

MoU signed with Lifera for localization and manufacturing of vaccines in the Kingdom, combined with knowledge and technology transfer to the Saudi workforce. Announced at Global Health Exhibition 2025.

lifera.com.sa
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-10-27
Description

Partnership signed at Global Health Exhibition 2025 to advance gene and cell therapy capabilities in Saudi Arabia. Collaboration aims to bring new expertise and technology into Saudi Arabia, strengthening national healthcare resilience.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-21
Description

Seven-year insulin localization partnership through Lifera's subsidiary SaudiBio. Novo Nordisk, the world's largest insulin producer, has agreed to localise insulin production in Saudi Arabia. Lifera will formulate, fill and finish insulin products. Saudi Arabia to become first producer of biologic innovator insulin in the region by 2027. Deal expected to create over 200 high-skilled jobs and facilitate technology transfer to Saudi workforce.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

U.S.-based CDMO with deep expertise in sterile injectable fill-finish, prefilled syringes, and biologics. Comparable to Lifera as a peer in isolator-based aseptic filling and multi-format drug product manufacturing for vaccines and biologics.

TypeDirect peer
Description

Switzerland-based global CDMO leader in biologics, cell and gene therapies, and small molecules. Comparable to Lifera as a direct competitor for mammalian cell culture, fill-finish, and modality-diverse contract manufacturing contracts with global pharma.

TypeDirect peer
Description

China-based global biologics CDMO offering end-to-end services from cell line development to commercial manufacturing. Comparable to Lifera as a peer in scaling commercial biologics capacity, biosimilars, and end-to-end CDMO services for global pharma clients.

TypeDirect peer
Description

U.S./U.K./Japan-based CDMO focused on biologics, vaccines, and gene therapy contract manufacturing. Comparable to Lifera in large-scale aseptic fill-finish, vaccine manufacturing, and process development for biologic modalities.

5Recipharm
TypeDirect peer
Description

Sweden-based CDMO with strong sterile injectable and prefilled syringe capabilities. Comparable to Lifera in aseptic fill-finish, drug product manufacturing, and contract services for biologics and complex injectables.

TypeDirect peer
Description

South Korea-based global biologics CDMO and one of the world's largest contract manufacturers of biopharmaceuticals. Directly comparable to Lifera as a from-scratch national champion building large-scale biologics capacity through sovereign backing, then scaling into a global CDMO.

TypeDirect peer
Description

Global CDMO offering mammalian and microbial-based biologics manufacturing, with strong fill-finish capabilities. Comparable to Lifera in multi-modality biologics CDMO services, including for vaccines and biosimilars.

TypeBroad incumbent
Description

Global life sciences giant offering comprehensive pharma services through its Patheon CDMO business, including sterile fill-finish and biologics. Comparable to Lifera as a broad incumbent CDMO competing for the same global pharma manufacturing contracts.

9Arabio (Arabian Agricultural & Veterinary Medicines Company)
TypeRegional player
Description

Saudi Arabia-based pharmaceutical manufacturer producing vaccines, biologics, and veterinary products. Comparable to Lifera as a regional Saudi pharmaceutical manufacturer operating in the same domestic market for biologics and vaccine localization.

10Boehringer Ingelheim BioXcellence
TypeDirect peer
Description

Germany-based biologics CDMO specializing in mammalian cell culture, mAb production, and aseptic fill-finish. Comparable to Lifera as a peer in large-molecule biologics contract manufacturing, including for biosimilars and innovator biopharma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lifera

Biopharmaceutical Contract Manufacturing (CDMO)lifera.com.sa

Lifera is a PIF-owned Saudi biopharmaceutical company operating SaudiBio for aseptic drug product CDMO manufacturing and Lifera Omics for genomic testing and bioinformatics, serving global pharmaceutical clients and regional healthcare providers.

What Lifera does

Lifera is a biopharmaceutical company established in June 2023 by Saudi Arabia's Public Investment Fund (PIF) to develop the Kingdom's domestic biopharmaceutical manufacturing capacity and enable the National Biotechnology Strategy under Vision 2030. The company is wholly owned by PIF (Saudi Arabia's sovereign wealth fund) and operates from Riyadh. It serves global pharmaceutical clients seeking to localize drug manufacturing in Saudi Arabia and the MENA region, as well as healthcare providers requiring genomic testing and precision medicine services. Lifera runs two core business units: Biomanufacturing, via subsidiary SaudiBio, focused on sterile and aseptic drug product and drug substance manufacturing; and Lifera Omics (MultiOmics), providing high-throughput genetic testing, bioinformatics, and research services.

The Biomanufacturing platform centers on the SaudiBio facility in Sudair Industrial City, 110 km north of Riyadh, built on a 30,000 sqm plot with expansion potential. Plant 1 features isolator-based, fully automated formulation and filling under cGMP, with capacity to produce up to 120 million annual units across vials (liquid and lyophilized) in 2R–50R formats, pre-filled syringes, and cartridges. Equipment is sourced from premium global suppliers including Syntegon, Groninger, SKAN, and Pierre Guerin, with commissioning targeted for 2027 under EMA Annex 1 and SFDA standards. The Lifera Omics business operates a proprietary biodatabank with over 800,000 patients (60,000+ Saudi Arabian) and over 70 million unique variants, supporting genomics, multiomic testing, and AI-enabled drug discovery focused on disease areas endemic to MENA populations.

Lifera's revenue model combines (1) CDMO services — manufacturing fees, technology transfer agreements, and long-term supply contracts — with global pharmaceutical partners (anchored by a seven-year insulin localization arrangement with Novo Nordisk, a Jamjoom Pharma 51/49 joint venture for vaccines/biologics/biosimilars, and exploratory MoUs with Pfizer, Sanofi, and MSD), and (2) genomic and multiomic testing, bioinformatics, and research services delivered to healthcare providers, hospitals, and biopharma clients. Pricing is enterprise quote-based and not publicly disclosed. Go-to-market is direct B2B engagement, supplemented by event-driven partnership announcements such as those made at the Global Health Exhibition 2025.

Lifera firmographics

Firmographics
Name
Lifera
Legal name
Lifera
Website
https://lifera.com.sa
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
51–100 employees
Short description
Lifera is a PIF-owned Saudi biopharmaceutical company operating SaudiBio for aseptic drug product CDMO manufacturing and Lifera Omics for genomic testing and bioinformatics, serving global pharmaceutical clients and regional healthcare providers.
Ownership category
akta.pro rank

Lifera industry classification

Industry
Product category
Biopharmaceutical Contract Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Biopharmaceutical manufacturing
  • Contract development manufacturing
  • Multiomics testing services
  • Genomic bioinformatics platform
  • Sterile drug product filling

Where Lifera is headquartered

Location

Headquarters

HQ city
Riyadh
HQ country
Saudi Arabia
HQ region
Middle East

Offices2 records

Markets served

Lifera business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Infrastructure, Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Biomanufacturing CDMO Services: Contract development and manufacturing organization providing commercial-scale drug product and drug substance manufacturing services to pharmaceutical companies. Revenue generated through manufacturing fees, technology transfer agreements, and long-term supply contracts with global pharma clients. SaudiBio facility performs formulation, fill, labeling and packaging of biotherapeutics, vaccines, and other biologics.
  2. Omics and Genetic Testing Services: Genomic and multiomic testing services provided to clinical, population health programs, and pharmaceutical clients. Revenue derived from diagnostic testing, bioinformatics services, and research partnerships with healthcare systems and biopharma companies.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Lifera product offering

Product offering

Core offering

Lifera provides commercial-scale contract development and manufacturing (CDMO) services for biopharmaceuticals through its subsidiary SaudiBio, covering drug substance and drug product manufacturing including formulation, aseptic filling, labeling, and packaging of biotherapeutics, vaccines, monoclonal antibodies, plasma therapeutics, cell and gene therapies, and innovative small molecules. The company also offers high-throughput genomic and multiomic testing, bioinformatics, and precision medicine services through Lifera Omics, supported by a proprietary biodatabank enriched for Saudi Arabian population genomics.

Product overview

Lifera is a biopharmaceutical company owned by Saudi Arabia's Public Investment Fund operating two primary business units: Biomanufacturing (including subsidiary SaudiBio) and Lifera Omics (MultiOmics). The Biomanufacturing division provides commercial-scale sterile drug product manufacturing services including formulation, fill, labeling, and packaging of biotherapeutics, vaccines, and other biologics, with SaudiBio Plant 1 targeting 120 million annual units capacity. The Lifera Omics platform delivers high-throughput genetic testing, bioinformatics, and precision medicine services powered by a proprietary biodatabank enriched for Saudi population genomic data. These offerings work together to enable end-to-end capabilities from genetic testing and drug discovery through commercial manufacturing of biologics, supporting Saudi Arabia's National Biotechnology Strategy and Vision 2030 goals.

Differentiator

Problem solved

Functional benefit

Brands

  • SaudiBio: State-of-the-art biopharmaceutical manufacturing facility located in Sudair Industrial City, 110 km north of Riyadh. Specializes in commercial drug product manufacturing including formulation, fill, labeling, and packaging of vials, prefilled syringes, and cartridges in both liquid and lyophilized formats.
  • Lifera Omics

Products and services

  • Biomanufacturing Services (CDMO) State-of-the-art sterile and aseptic biopharmaceutical drug product and drug substance manufacturing services including formulation, fill, labeling, and packaging of biotherapeutics, vaccines, monoclonal antibodies, plasma therapeutics, cell and gene therapies, and innovative small molecules. Provided through the SaudiBio facility with isolator-based, fully automated cGMP-aligned filling lines and up to 120 million annual units capacity across liquid and lyophilized formats for vials, prefilled syringes, and cartridges. Targeted at global pharmaceutical companies seeking manufacturing localization.
  • Lifera Omics (MultiOmics Testing and Bioinformatics Services) High-throughput genomic and multiomic testing, bioinformatics, and precision medicine services for clinical diagnostics, population health programs, and pharmaceutical research clients. Powered by a proprietary biodatabank with over 800,000 patients including 60,000+ Saudi Arabian individuals and 70+ million unique variants. Provided to healthcare providers, hospitals, research centers, and biopharma R&D teams in compliance with HIPAA, GDPR, and Saudi PDPL.

Quantifiable outcome

  • Expected to create over 200 high-skilled jobs in Saudi Arabia by 2027/28 through Novo Nordisk insulin localization
  • +2 more outcomes

Companies that use Lifera

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Lifera technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Lifera partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, major and strategic.

  • Jamjoom PharmacoreStrategic or Co-development Partner · 27 October 2025Joint venture announced at Global Health Exhibition for development, manufacture, and commercialization of vaccines, biologics, and biosimilars in Saudi Arabia. Lifera holds 51% majority stake, Jamjoom Pharma holds 49% through subscription to 4,900 shares at SAR 100 per share. JV to build, own, and operate a manufacturing facility in Saudi Arabia. Transaction received no-objection certificate from General Authority for Competition.
  • Pfizer Saudi ArabiamajorStrategic or Co-development Partner · 27 October 2025MoU signed at Global Health Exhibition 2025 to explore local pharmaceutical manufacturing opportunities in Saudi Arabia. Partnership supports Saudi Vision 2030 goals for biopharmaceutical industry development, technology transfer, and reducing reliance on pharmaceutical imports. Aims to position Saudi Arabia as a regional life sciences hub while strengthening Saudi-U.S. investment ties.
  • SanofimajorStrategic or Co-development Partner · 27 October 2025MoU signed with Lifera to explore vaccine production opportunities in Saudi Arabia. Partnership announced at Global Health Exhibition 2025 as part of broader life sciences investments exceeding $625 million at the event.
  • MSDmajorStrategic or Co-development Partner · 27 October 2025MoU signed with Lifera for localization and manufacturing of vaccines in the Kingdom, combined with knowledge and technology transfer to the Saudi workforce. Announced at Global Health Exhibition 2025.
  • King Faisal Specialist Hospital & Research CentrestrategicStrategic or Co-development Partner · 27 October 2025Partnership signed at Global Health Exhibition 2025 to advance gene and cell therapy capabilities in Saudi Arabia. Collaboration aims to bring new expertise and technology into Saudi Arabia, strengthening national healthcare resilience.
  • Novo Nordisk Saudi ArabiacoreStrategic or Co-development Partner · 21 October 2024Seven-year insulin localization partnership through Lifera's subsidiary SaudiBio. Novo Nordisk, the world's largest insulin producer, has agreed to localise insulin production in Saudi Arabia. Lifera will formulate, fill and finish insulin products. Saudi Arabia to become first producer of biologic innovator insulin in the region by 2027. Deal expected to create over 200 high-skilled jobs and facilitate technology transfer to Saudi workforce.

Scale indicators7 records

Recent moves6 records

Expansion highlights7 records

Lifera competitors and assessment

Company assessment

Direct peers

  • Catalent: U.S.-based CDMO with deep expertise in sterile injectable fill-finish, prefilled syringes, and biologics. Comparable to Lifera as a peer in isolator-based aseptic filling and multi-format drug product manufacturing for vaccines and biologics.
  • Lonza Group: Switzerland-based global CDMO leader in biologics, cell and gene therapies, and small molecules. Comparable to Lifera as a direct competitor for mammalian cell culture, fill-finish, and modality-diverse contract manufacturing contracts with global pharma.
  • WuXi Biologics: China-based global biologics CDMO offering end-to-end services from cell line development to commercial manufacturing. Comparable to Lifera as a peer in scaling commercial biologics capacity, biosimilars, and end-to-end CDMO services for global pharma clients.
  • FUJIFILM Diosynth Biotechnologies: U.S./U.K./Japan-based CDMO focused on biologics, vaccines, and gene therapy contract manufacturing. Comparable to Lifera in large-scale aseptic fill-finish, vaccine manufacturing, and process development for biologic modalities.
  • Recipharm: Sweden-based CDMO with strong sterile injectable and prefilled syringe capabilities. Comparable to Lifera in aseptic fill-finish, drug product manufacturing, and contract services for biologics and complex injectables.
  • Samsung Biologics: South Korea-based global biologics CDMO and one of the world's largest contract manufacturers of biopharmaceuticals. Directly comparable to Lifera as a from-scratch national champion building large-scale biologics capacity through sovereign backing, then scaling into a global CDMO.
  • AGC Biologics: Global CDMO offering mammalian and microbial-based biologics manufacturing, with strong fill-finish capabilities. Comparable to Lifera in multi-modality biologics CDMO services, including for vaccines and biosimilars.
  • Boehringer Ingelheim BioXcellence: Germany-based biologics CDMO specializing in mammalian cell culture, mAb production, and aseptic fill-finish. Comparable to Lifera as a peer in large-molecule biologics contract manufacturing, including for biosimilars and innovator biopharma.

Broad incumbents

  • Thermo Fisher Scientific (CDMO / Patheon): Global life sciences giant offering comprehensive pharma services through its Patheon CDMO business, including sterile fill-finish and biologics. Comparable to Lifera as a broad incumbent CDMO competing for the same global pharma manufacturing contracts.

Regional players

  • Arabio (Arabian Agricultural & Veterinary Medicines Company): Saudi Arabia-based pharmaceutical manufacturer producing vaccines, biologics, and veterinary products. Comparable to Lifera as a regional Saudi pharmaceutical manufacturer operating in the same domestic market for biologics and vaccine localization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Lifera social profiles

Digital presence

Lifera compliance and trust

Trust signal

Compliance4 records

Lifera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lifera leadership team

Management profile

Number of profiles

Profiles8 records

Lifera subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Lifera funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lifera M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lifera

What does Lifera do?

Lifera provides commercial-scale contract development and manufacturing (CDMO) services for biopharmaceuticals through its subsidiary SaudiBio, covering drug substance and drug product manufacturing including formulation, aseptic filling, labeling, and packaging of biotherapeutics, vaccines, monoclonal antibodies, plasma therapeutics, cell and gene therapies, and innovative small molecules. The company also offers high-throughput genomic and multiomic testing, bioinformatics, and precision medicine services through Lifera Omics, supported by a proprietary biodatabank enriched for Saudi Arabian population genomics.

Is Lifera a public or private company?

Lifera is a private company. It is classified as state government owned and is currently operating.

When was Lifera founded?

Lifera was founded in 2023. It employs 51 to 100 people.

Where is Lifera based?

Lifera is headquartered in Riyadh, Saudi Arabia, in the Middle East region.

How does Lifera make money?

Two revenue lines are on record. Biomanufacturing CDMO Services are the primary driver. The others are omics and Genetic Testing Services.

Who are Lifera's main competitors?

Direct peers on record are Catalent, Lonza Group, WuXi Biologics, FUJIFILM Diosynth Biotechnologies, Recipharm, Samsung Biologics, AGC Biologics and Boehringer Ingelheim BioXcellence. Thermo Fisher Scientific (CDMO / Patheon) is listed as a broad incumbent. Arabio (Arabian Agricultural & Veterinary Medicines Company) is listed as a regional player.

Does Lifera have an API?

No public API is recorded for Lifera.

What industry is Lifera in?

Lifera's product category is Biopharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Fast Company Middle EastSaudi Arabia and the UAE are building a bio-economy out of genomics, biofuels, and diagnosticsSaudi Arabia and the UAE are developing a unified bio-economy strategy spanning genomics, biofuels, and diagnostics, moving from decades of medical imports toward domestic production and eventual exports. Key milestones include Lifera Omics' bio databank with over 60,000 Saudi patients, MENA Biofuels' first commercial sustainable aviation fuel plant in Fujairah producing 125 million liters annually, and Saudi Arabia's target to localize 40% of drug manufacturing by 2032. The shift from venture capital and memorandums of understanding toward physical infrastructure and construction tenders signals that Gulf capital has moved into heavy industrial deployment, with the three sectors operating under a single doctrine of sovereign resilience and security.CMSWire.comThe AEO-SEO Readiness Playbook Every Marketing Team NeedsThis article is an opinion/guide piece by a Liferay team member presenting an internal playbook for optimizing content for both traditional search engines and AI-mediated search environments. The author argues that content must now perform in two distinct environments simultaneously, requiring investments in clean heading hierarchy, schema markup, and descriptive internal linking. The guide emphasizes tracking 'share of model' in LLM responses as a new measurement metric and advocates for allowing AI crawlers access via robots.txt configuration.openPR.comLeading Companies Spearheading Innovation and Growth in the Contract Development Manufacturing Organizations MarketThe CDMO market is projected to reach $503.82 billion by 2030, growing at a 12.9% CAGR, driven by biologics advancement, flexible production needs, and growth in small and mid-size pharmaceutical companies. In December 2023, Japan-based Ajinomoto Co., Inc. acquired Forge Biologics for $620 million to expand its capabilities in viral vectors and plasmid gene therapies for the gene therapy market. In June 2023, Saudi Arabia's Public Investment Fund launched Lifera as a commercial-scale CDMO to boost domestic pharmaceutical manufacturing capacity.EIN PresswireLifera and Jamjoom Pharma Launch Strategic Joint Venture to Power Saudi Arabia’s Biopharma FutureLifera (a PIF company) and Jamjoom Pharma announced a potential joint venture at the Global Health Exhibition in Riyadh to develop, manufacture, and commercialize vaccines, biologics, and biosimilars in Saudi Arabia. The partnership aims to strengthen the Kingdom's biopharma manufacturing ecosystem and reduce import dependency, supporting Saudi Arabia's National Biotechnology Strategy to become a regional and global biotechnology leader by 2040. The transaction is subject to definitive documentation and relevant regulatory approvals.EIN PresswireGLOBAL HEALTH EXHIBITION 2025 OPENS WITH LANDMARK AGREEMENTS ANNOUNCED WORTH MORE THAN $33 BILLION USDThe Global Health Exhibition 2025 opened in Riyadh, Saudi Arabia, on October 28, 2025, with agreements worth more than $33 billion USD announced across hospital infrastructure, life sciences, and venture capital investments. Key announcements included an $8.4 billion investment in hospitals and healthcare infrastructure, with Hayat National Hospitals ($1.86B), Akdital Group ($1.41B), Mouwasat ($1.33B), and Alrajhi Medicine (over $1B) among the major investors. The exhibition also featured life sciences investments exceeding $625 million, including partnerships between Lifera and global pharmaceutical companies Sanofi, MSD, Pfizer, and Jamjoom Pharma, alongside $3.24 billion in venture capital commitments from investors such as Hillhouse ($1.49B) and Al Fozan Holding ($675M).SemaforSaudi Arabia’s health push goes high-techSaudi Arabia is set to announce approximately $33 billion in healthcare deals at the Global Health Exhibition in Riyadh, with over 160,000 attendees expected. Lifera, a unit of the kingdom's $1 trillion sovereign wealth fund, has signed cooperation agreements with MSD, Pfizer, and Sanofi to localize production of pharmaceuticals and vaccines domestically. Additionally, Google plans to launch an AI-powered health coach for Saudi citizens and conduct clinical trials for AI physicians in the kingdom.GulfNewsPfizer Saudi Arabia, PIF's Lifera to explore local drug manufacturingPfizer Saudi Arabia and Lifera, a Public Investment Fund (PIF) company, signed a Memorandum of Understanding at the Global Health Exhibition 2025 in Riyadh to explore local pharmaceutical manufacturing opportunities in Saudi Arabia. The agreement supports Saudi Vision 2030 goals for biopharmaceutical industry development, technology transfer, and reducing reliance on pharmaceutical imports. The partnership aims to position Saudi Arabia as a regional life sciences hub while strengthening Saudi-U.S. investment ties through knowledge exchange and workforce development.GlobeNewswireSaudi Arabia Pharmaceutical CDMO Market Research Report 2025 Featuring Tabuk Manufacturing, Lifera, Saudi Bio, Fresenius Kabi, Hikma Pharma, Pfizer, NovartisThe Saudi Arabia pharmaceutical CDMO market is projected to grow from $1.62 billion in 2024 to $2.24 billion by 2030, a 5.45% CAGR. Growth is driven by Vision 2030, rising domestic demand, and health system modernization, with challenges including regulatory barriers and skilled labor shortages.